Product Description
Mechanisms of Action: Protease Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: China | India | Ukraine
Approved Indications: None
Known Adverse Events: None
Company: Zhejiang University
Company Location: Asia Pacific
Company Founding Year: 1897
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Congenital Heart Defects|Inflammation|Other|Reperfusion Injury|Coronary Artery Disease|Pancreatitis|Shock, Septic|Injuries/wounds Unspecified
Phase 3: Mucositis|Nasopharyngeal Cancer|Stomatitis|Oral Ulcer|Sepsis
Phase 2: COVID-19|Respiratory Aspiration|Lung Injury|Acute Lung Injury|Respiratory Distress Syndrome, Newborn|Acute Respiratory Distress Syndrome
Phase 1: Acute Lung Injury
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ChiCTR2300074837 |
ChiCTR2300074837 | N/A |
Recruiting |
Coronary Disease|Kidney Diseases|Acute Kidney Injury |
2033-08-31 |
2024-01-14 |
Treatments |
|
ChiCTR2500114959 |
ChiCTR2500114959 | N/A |
Not yet recruiting |
Sepsis |
2026-12-31 |
|||
NCT07382375 |
PANDA-Smart | N/A |
Not yet recruiting |
Aortic Aneurysm|Inflammation |
2027-12-31 |
2026-02-03 |
||
NCT06966687 |
PANDA XI | N/A |
Enrolling by invitation |
Aortic Aneurysm |
2026-12-31 |
2025-05-14 |
Primary Endpoints |
|
ChiCTR2500095855 |
ChiCTR2500095855 | N/A |
Recruiting |
Spinal Stenosis|Spondylolisthesis |
2026-12-31 |
|||
ChiCTR2300072139 |
ChiCTR2300072139 | N/A |
Recruiting |
Pancreatitis, Acute |
2026-06-30 |
2023-06-09 |
Treatments |
|
ChiCTR2500103934 |
ChiCTR2500103934 | N/A |
Recruiting |
Unknown |
2026-06-09 |
|||
ChiCTR2500110759 |
ChiCTR2500110759 | N/A |
Recruiting |
Sepsis |
2026-04-30 |
|||
ChiCTR2400080349 |
ChiCTR2400080349 | N/A |
Not yet recruiting |
Sepsis |
2025-12-31 |
2024-01-27 |
Treatments |
|
ChiCTR2400091262 |
ChiCTR2400091262 | N/A |
Not yet recruiting |
Pancreatitis, Acute |
2025-07-01 |
|||
ChiCTR2500096907 |
The application of Ulinastatin in postoperative analgesia following knee/hip arthroplasty. | N/A |
Not yet recruiting |
Pain, Postoperative|Acute Pain |
2025-06-30 |
|||
ChiCTR2300079180 |
ChiCTR2300079180 | N/A |
Recruiting |
Unknown |
2025-06-01 |
2023-12-27 |
Treatments |
|
ChiCTR2500102668 |
ChiCTR2500102668 | N/A |
Recruiting |
Pancreatitis, Acute |
2025-05-31 |
|||
ChiCTR2500097826 |
ChiCTR2500097826 | N/A |
Recruiting |
Morphine Dependence|Pain, Postoperative |
2025-05-31 |
|||
ChiCTR2200058102 |
ChiCTR2200058102 | N/A |
Not yet recruiting |
Inflammation |
2024-12-31 |
2023-03-12 |
Treatments |
|
NCT05534802 |
TJ-IRB20220831 | N/A |
Completed |
Acute Kidney Injury|Stroke|Environmental Hypersensitivity|Animal Hypersensitivity|Kidney Diseases|Drug Hypersensitivity|Pulmonary Edema|Anesthesia Related|Dyslipidemia|Pulmonary Heart Disease|Hypertension, Pulmonary|Coronary Artery Disease|Cardiac Arrest|Edema, Cardiac |
2024-12-30 |
2025-01-22 |
Primary Endpoints |
|
NCT07090278 |
SAE-UTI | N/A |
Completed |
Sepsis-Associated Encephalopathy|Brain Diseases |
2024-10-31 |
2025-08-01 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date |
|
ChiCTR2300072126 |
ChiCTR2300072126 | N/A |
Not yet recruiting |
Pain, Postoperative |
2024-05-30 |
2023-07-29 |
Treatments |
|
ChiCTR2300074039 |
ChiCTR2300074039 | N/A |
Recruiting |
Pain, Postoperative |
2024-03-31 |
2023-11-04 |
Patient Enrollment |
|
ChiCTR2000035702 |
ChiCTR2000035702 | N/A |
Recruiting |
Acute Respiratory Distress Syndrome |
2023-12-31 |
|||
ChiCTR2200057974 |
ChiCTR2200057974 | N/A |
Not yet recruiting |
Brain Cancer|Meningioma|Brain Edema |
2023-12-31 |
|||
ChiCTR2100043950 |
ChiCTR2100043950 | N/A |
Recruiting |
Cognitive Dysfunction |
2023-12-31 |
|||
ChiCTR2200059084 |
ChiCTR2200059084 | N/A |
Recruiting |
Cognitive Dysfunction |
2023-12-31 |
|||
ChiCTR2300072391 |
ChiCTR2300072391 | N/A |
Recruiting |
Pancreatic Cancer |
2023-12-31 |
2023-06-14 |
Treatments |
|
ChiCTR2200057516 |
ChiCTR2200057516 | N/A |
Recruiting |
Other |
2023-12-30 |